CNXC
Concentrix Corporation NASDAQ Listed Nov 24, 2020$25.46
Mkt Cap $1.6B
52w Low $22.85
6.7% of range
52w High $62.14
50d MA $28.98
200d MA $40.20
P/E (TTM)
-1.2x
EV/EBITDA
-27.4x
P/B
0.6x
Debt/Equity
1.7x
ROE
-47.6%
P/FCF
4.0x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$28.98
200d MA
$40.20
Avg Volume
1.6M
Concentrix Corporation provides technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services. It also offers customer lifecycle management; customer experience/user experience strategy and design; digital transformation; and voice of the customer and analytics solutions. The company's clients include consumer electronics, technology, e-commerce, and health insurance companies, as well as global IPOs, social brands, and banks. Concentrix Corporation was incorporated in 2009 and is based in Fremont, California.
44111 Nobel Drive · Newark, CA 94538 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | 2.64 | 2.61 | -1.1% | 26.48 | -0.6% | -6.8% | +4.7% | -0.2% | +0.8% | +3.3% | — |
| Jan 13, 2026 | AMC | 2.91 | 2.95 | +1.4% | 39.18 | +0.9% | +5.7% | +7.7% | +10.1% | +2.4% | +6.5% | — |
| Sep 25, 2025 | AMC | 2.88 | 2.78 | -3.5% | 54.99 | -21.5% | -13.3% | -13.0% | -16.1% | -12.3% | -13.0% | — |
| Jun 26, 2025 | AMC | 2.76 | 2.70 | -2.2% | 55.13 | -6.1% | -6.2% | -4.1% | +2.0% | +3.0% | +3.7% | — |
| Mar 26, 2025 | AMC | 2.58 | 2.79 | +8.1% | 45.68 | +12.7% | +42.4% | +24.7% | +21.8% | +18.3% | +18.7% | — |
| Jan 15, 2025 | AMC | 3.00 | 3.26 | +8.7% | 47.47 | -1.1% | +2.8% | +3.1% | +6.6% | +6.0% | +10.5% | — |
| Sep 25, 2024 | AMC | 2.90 | 2.87 | -1.0% | 63.62 | -14.0% | -19.0% | -19.0% | -19.4% | -19.9% | -18.7% | — |
| Jun 26, 2024 | AMC | 2.62 | 2.69 | +2.7% | 58.02 | +13.9% | +8.2% | +9.1% | +9.9% | +13.7% | +13.7% | — |
| Mar 26, 2024 | AMC | 2.58 | 2.57 | -0.4% | 62.23 | -3.6% | +4.8% | +6.4% | +1.8% | -1.2% | -7.6% | — |
| Jan 24, 2024 | AMC | 3.09 | 3.36 | +8.7% | 103.90 | -9.1% | -16.0% | -12.3% | -11.3% | -13.6% | -14.5% | — |
| Sep 27, 2023 | AMC | 2.76 | 2.71 | -1.8% | 73.97 | -0.3% | +6.8% | +8.3% | +8.5% | +5.9% | +8.1% | — |
| Jun 28, 2023 | AMC | 2.78 | 2.69 | -3.2% | 83.48 | -4.8% | -3.2% | -3.3% | -0.4% | -1.6% | -4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $26.48 | $26.31 | -0.6% | -6.8% | +4.7% | -0.2% | +0.8% | +3.3% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $26.48 | $26.31 | -0.6% | -6.8% | +4.7% | -0.2% | +0.8% | +3.3% |
| Mar 25 | Barrington Research | Maintains | Outperform → Outperform | — | $26.48 | $26.31 | -0.6% | -6.8% | +4.7% | -0.2% | +0.8% | +3.3% |
| Mar 17 | Barrington Research | Maintains | Outperform → Outperform | — | $31.96 | $32.25 | +0.9% | +2.9% | -3.7% | -0.1% | -1.4% | +3.4% |
| Jan 12 | Barrington Research | Maintains | Outperform → Outperform | — | $44.06 | $43.83 | -0.5% | -8.1% | -11.1% | -6.0% | -4.3% | -2.1% |
| Nov 20 | Barrington Research | Maintains | Outperform → Outperform | — | $32.91 | $32.96 | +0.2% | +1.4% | +8.3% | +7.4% | +8.6% | +7.9% |
| Sep 29 | Baird | Maintains | Outperform → Outperform | — | $47.66 | $47.84 | +0.4% | +0.4% | -3.2% | +1.2% | +0.4% | +1.3% |
| Sep 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $54.99 | $43.18 | -21.5% | -13.3% | -13.0% | -16.1% | -12.3% | -13.0% |
| Sep 26 | Barrington Research | Maintains | Outperform → Outperform | — | $54.99 | $43.18 | -21.5% | -13.3% | -13.0% | -16.1% | -12.3% | -13.0% |
| Sep 24 | Barrington Research | Maintains | Outperform → Outperform | — | $55.09 | $55.09 | +0.0% | +0.9% | -0.2% | -13.5% | -13.2% | -16.2% |
| Sep 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $55.53 | $55.62 | +0.2% | -0.8% | +0.1% | -1.0% | -14.2% | -13.9% |
| Sep 18 | Baird | Maintains | Outperform → Outperform | — | $55.49 | $56.79 | +2.3% | +2.9% | +2.7% | +0.1% | -0.7% | +0.2% |
| Jun 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $51.71 | $52.56 | +1.6% | +2.2% | +8.7% | +9.8% | +10.5% | +9.6% |
| Jun 27 | Barrington Research | Maintains | Outperform → Outperform | — | $55.13 | $51.77 | -6.1% | -6.2% | -4.1% | +2.0% | +3.0% | +3.7% |
| Jun 27 | BofA Securities | Maintains | Neutral → Neutral | — | $55.13 | $51.77 | -6.1% | -6.2% | -4.1% | +2.0% | +3.0% | +3.7% |
| Jun 26 | Baird | Maintains | Outperform → Outperform | — | $54.17 | $55.94 | +3.3% | +1.8% | -4.5% | -2.4% | +3.8% | +4.8% |
| Jun 24 | Barrington Research | Maintains | Outperform → Outperform | — | $51.77 | $52.85 | +2.1% | +4.5% | +4.6% | +6.5% | -0.1% | +2.1% |
| Jun 9 | BofA Securities | Maintains | Neutral → Neutral | — | $56.61 | $57.00 | +0.7% | -1.4% | +0.0% | +1.3% | +1.0% | -2.3% |
| Mar 27 | BofA Securities | Maintains | Neutral → Neutral | — | $45.68 | $51.49 | +12.7% | +42.4% | +24.7% | +21.8% | +18.3% | +18.7% |
| Mar 27 | Barrington Research | Maintains | Outperform → Outperform | — | $45.68 | $51.49 | +12.7% | +42.4% | +24.7% | +21.8% | +18.3% | +18.7% |
| Mar 24 | Barrington Research | Maintains | Outperform → Outperform | — | $44.93 | $45.01 | +0.2% | +0.2% | +0.6% | +1.7% | +44.8% | +26.8% |
| Jan 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $47.47 | $46.96 | -1.1% | +2.8% | +3.1% | +6.6% | +6.0% | +10.5% |
| Sep 26 | BofA Securities | Maintains | Neutral → Neutral | — | $63.62 | $54.70 | -14.0% | -19.0% | -19.0% | -19.4% | -19.9% | -18.7% |
| Sep 26 | Barrington Research | Maintains | Outperform → Outperform | — | $63.62 | $54.70 | -14.0% | -19.0% | -19.0% | -19.4% | -19.9% | -18.7% |
| Sep 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $63.62 | $54.70 | -14.0% | -19.0% | -19.0% | -19.4% | -19.9% | -18.7% |
| Sep 23 | Barrington Research | Maintains | Outperform → Outperform | — | $63.38 | $63.38 | +0.0% | +0.3% | +0.7% | +0.4% | -18.7% | -18.6% |
| Sep 20 | Barrington Research | Maintains | Outperform → Outperform | — | $64.17 | $63.80 | -0.6% | -1.2% | -1.0% | -0.5% | -0.9% | -19.7% |
| Aug 28 | BofA Securities | Upgrade | Underperform → Neutral | — | $72.34 | $73.19 | +1.2% | +3.2% | +4.5% | +4.0% | +3.1% | +4.1% |
| Jun 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $58.02 | $66.09 | +13.9% | +8.2% | +9.1% | +9.9% | +13.7% | +13.7% |
| Jun 21 | Barrington Research | Maintains | Outperform → Outperform | — | $60.46 | $60.47 | +0.0% | +0.3% | -0.8% | -2.7% | -4.0% | +3.8% |
| Apr 29 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $55.01 | $55.01 | +0.0% | +2.0% | -0.6% | +0.5% | +4.1% | +7.9% |
| Mar 27 | Barrington Research | Maintains | Outperform → Outperform | — | $62.23 | $59.96 | -3.6% | +4.8% | +6.4% | +1.8% | -1.2% | -7.6% |
| Mar 27 | BofA Securities | Downgrade | Neutral → Underperform | — | $62.23 | $59.96 | -3.6% | +4.8% | +6.4% | +1.8% | -1.2% | -7.6% |
| Mar 20 | Barrington Research | Maintains | Outperform → Outperform | — | $60.08 | $59.76 | -0.5% | +4.5% | +4.8% | +2.0% | +4.2% | +3.6% |
| Jan 25 | Barrington Research | Maintains | Outperform → Outperform | — | $103.90 | $94.41 | -9.1% | -16.0% | -12.3% | -11.3% | -13.6% | -14.5% |
| Jun 29 | BofA Securities | Downgrade | Buy → Neutral | — | $83.48 | $79.49 | -4.8% | -3.2% | -3.3% | -0.4% | -1.6% | -4.0% |
| Jun 29 | Barrington Research | Maintains | Outperform → Outperform | — | $83.48 | $79.49 | -4.8% | -3.2% | -3.3% | -0.4% | -1.6% | -4.0% |
| Jun 26 | Barrington Research | Maintains | Outperform → Outperform | — | $81.59 | $81.50 | -0.1% | +1.7% | +2.6% | +2.3% | -1.0% | -1.0% |
| Apr 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $111.00 | $113.65 | +2.4% | +0.6% | +1.2% | -0.6% | -0.6% | -1.7% |
| Mar 30 | Barrington Research | Maintains | Outperform → Outperform | — | $121.77 | $116.00 | -4.7% | -1.5% | -0.2% | -1.5% | -5.0% | -7.3% |
| Mar 27 | Barrington Research | Maintains | Outperform → Outperform | — | $117.63 | $118.90 | +1.1% | +2.5% | +1.7% | +3.5% | +2.0% | +3.3% |
| Sep 30 | Barrington Research | Maintains | Outperform → Outperform | — | $109.76 | $109.85 | +0.1% | +1.7% | +7.1% | +11.1% | +11.7% | +13.5% |
| Jul 5 | Barrington Research | Maintains | Outperform → Outperform | — | $137.14 | $134.85 | -1.7% | -1.6% | -5.1% | -3.9% | -3.2% | -6.0% |
| Jun 15 | Barrington Research | Maintains | Outperform → Outperform | — | $152.13 | $152.96 | +0.5% | -0.5% | +0.5% | +1.8% | +5.2% | +2.4% |
| Jan 8 | Cross Research | Maintains | Buy → Buy | — | $102.86 | $104.45 | +1.5% | +6.8% | +8.7% | +15.2% | +16.4% | +19.4% |
| Dec 7 | BofA Securities | Maintains | Buy → Buy | — | $101.21 | $101.47 | +0.3% | +13.8% | +3.1% | +1.5% | -0.5% | -1.1% |
| Oct 16 | Citigroup | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 9 | Jefferies | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Oct 4 | Jefferies | Maintains | Hold → Hold | — | — | — | — | — | — | — | — | — |
| Sep 19 | Jefferies | Maintains | Hold → Hold | — | — | — | — | — | — | — | — | — |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | Groupe Bruxelles Lambert | — | Sell | 6,000,000 | $22.25 | $133.5M | 2,773,667 | -4.16% | — |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CNXC's shareholder-approved increase in equity plan shares will likely dilute existing shareholders but signals management confidence in long-term growth prospects, warranting evaluation of dilution versus growth strategy.
Mar 27
8-K
Unknown — 8-K Filing
Concentrix's 5.4% YoY revenue growth and maintained full-year guidance suggest stable execution, though modest growth warrants monitoring whether iX Suite momentum can accelerate returns for shareholders.
Mar 24
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CNXC secured receivables financing, likely indicating cash flow needs and potential dilution, which could pressure the stock unless the capital fuels significant growth.
Mar 23
8-K · 1.01
! Medium
Concentrix Corporation -- 8-K 1.01: Financing / Debt Agreement
Concentrix Corporation entered into a financing or debt agreement with arrangements involving payments to Cede & Co., indicating a secured debt transaction affecting the company's capital structure.
Feb 24
8-K · 8.01
!! High
Concentrix Corporation -- 8-K 8.01: Material Event / Announcement
Concentrix will raise $600 million through senior notes offering at 6.5% coupon due 2029, providing capital for potential acquisitions, debt refinancing, or operational expansion.
Feb 13
Data updated apr 25, 2026 2:24am
· Source: massive.com